DOTmed August 2, 2024
Gus Iversen

R1 RCM Inc., based in Murray, Utah, has been acquired by private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) for approximately $8.9 billion in cash. TowerBrook, which already owns about 36% of R1’s shares, and CD&R will buy out the remaining shares for $14.30 each.

The acquisition price marks a 29% premium over R1’s closing stock price on February 23, 2024, prior to New Mountain Capital’s initial non-binding acquisition proposal. The deal has received unanimous approval from a special committee of R1’s board of directors, composed solely of independent directors. The committee led the negotiations, advised by independent legal and financial advisors.

“TowerBrook has been an outstanding long-term investor and partner to R1 and shares our...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mergers & Acquisitions / JV, RCM (Revenue Cycle Mgmt), Technology, Trends
Aspirion lands 7th acquisition in 6 years
Revenue Cycle Risk Takers
Revenue Cycle AI Is Costly and Cumbersome. Here's Why Leaders Are Still Buying In.
Medical Tourism and Global Private Healthcare Drive Revenue Cycle Innovation: Black Book Report
4 Cornerstones for Successful AI Implementation in Hospital Revenue Cycle Management in 2025

Share This Article